



BREAKTHROUGH PEPTIDE THERAPEUTICS

## Non-Executive Director Appointment

**Perth, Australia, 18 January 2016:** Phylogica Limited (ASX: PYC) have appointed Ms Stephanie Unwin as a non-executive director of the Company.

Ms Unwin is currently Synergy's Chief Transformation Officer, leading a 12-18 month, whole-of-business operational efficiency program.

Ms Unwin's substantive role is General Manager, Commercial - a role she has held since March 2014 and which encompasses Strategy and Innovation; Corporate Development; Modelling and Analytics; Public Affairs and Corporate Communications; Policy and the Chief Engineer. Stephanie held the role of General Manager Strategy and Business Development with Verve Energy prior to its merger with Synergy.

Stephanie's background is in corporate law, and she previously worked with ASIC, Herbert Smith Freehills, Pullinger Readhead Stewart and Maxim Litigation Consultants before joining Verve Energy as its General Counsel and Company Secretary in 2008.

Stephanie is a former non-executive director of ASX/TSX listed entity Alacer Gold Corp (December 2001 to August 2013) and ASX listed entity Integra Mining Limited (November 2011 to January 2013). She is currently a director of Vinalco Energy Pty Ltd, Greenough River Solar Farm Pty Ltd and Mumbida Wind Farm Pty Ltd and a board member of the Australian Prospectors and Miners Hall of Fame.

Phylogica Chairman Bruce McHarrie said "We are delighted to be joined Ms Unwin who brings exceptional senior level experience and skills in corporate strategy and innovation which are highly complementary to our existing Board. This appointment will enhance Phylogica's strategic positioning domestically and internationally."

**For further information, please contact:**

Dr Richard Hopkins

Tel: +61 8 9489 7855

Email: richardh@phylogica.com

***About Phylogica***

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics from the most structurally diverse libraries available. The Company listed on the ASX in 2005 as a spin out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company's drug discovery platform is based on its proprietary Phylomer® libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to adopt stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer® libraries and proprietary screening technologies in exchange for licence fees, milestones and royalties. Partners from discovery alliances within the last 5 years include Roche, MedImmune, Pfizer, Janssen, Cubist Pharmaceuticals and Genentech.

---

PO Box 8207, Subiaco East, Western Australia 6008

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

[www.phylogica.com](http://www.phylogica.com)

**Phylogica Ltd**

ABN 48 098 391 961